These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 28124526)
1. Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range. Vukovic I; Djordjevic D; Bojanic N; Babic U; Soldatovic I Int Braz J Urol; 2017; 43(1):48-56. PubMed ID: 28124526 [TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022 [TBL] [Abstract][Full Text] [Related]
3. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years. Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705 [TBL] [Abstract][Full Text] [Related]
4. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination. Lazzeri M; Abrate A; Lughezzani G; Gadda GM; Freschi M; Mistretta F; Lista G; Fossati N; Larcher A; Kinzikeeva E; Buffi N; Dell'Acqua V; Bini V; Montorsi F; Guazzoni G Urology; 2014 Mar; 83(3):606-12. PubMed ID: 24315305 [TBL] [Abstract][Full Text] [Related]
5. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841 [TBL] [Abstract][Full Text] [Related]
6. Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml. Furuya K; Kawahara T; Narahara M; Tokita T; Fukui S; Imano M; Mitome T; Ito Y; Izumi K; Osaka K; Yokomizo Y; Hayashi N; Hasumi H; Nawata S; Kawano T; Yao M; Uemura H Scand J Urol; 2017 Aug; 51(4):251-257. PubMed ID: 28351193 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study. Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975 [TBL] [Abstract][Full Text] [Related]
8. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center. Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925 [TBL] [Abstract][Full Text] [Related]
9. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333 [TBL] [Abstract][Full Text] [Related]
10. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961 [TBL] [Abstract][Full Text] [Related]
11. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study. Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786 [TBL] [Abstract][Full Text] [Related]
12. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination. Chiu PK; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF Investig Clin Urol; 2016 Sep; 57(5):336-42. PubMed ID: 27617315 [TBL] [Abstract][Full Text] [Related]
13. Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study. Fossati N; Lazzeri M; Haese A; McNicholas T; de la Taille A; Buffi NM; Lughezzani G; Gadda GM; Lista G; Larcher A; Abrate A; Mistretta F; Bini V; Redorta JP; Graefen M; Guazzoni G BJU Int; 2015 Jun; 115(6):913-20. PubMed ID: 24589357 [TBL] [Abstract][Full Text] [Related]
14. Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL. Ferro M; Crocetto F; La Civita E; Fiorenza M; Jannuzzi G; Carbone G; Sirica R; Sicignano E; Pagano G; Imbimbo C; Terracciano D Prostate; 2024 Sep; 84(12):1157-1164. PubMed ID: 38798011 [TBL] [Abstract][Full Text] [Related]
15. Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography. Yu GP; Na R; Ye DW; Qi J; Liu F; Chen HT; Wu YS; Zhang GM; Sun JL; Zhu Y; Huang LQ; Ren SC; Jiang DK; Zheng SL; Jiang HW; Sun YH; Ding Q; Xu J Asian J Androl; 2016; 18(4):633-8. PubMed ID: 26975483 [TBL] [Abstract][Full Text] [Related]
16. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. Fossati N; Buffi NM; Haese A; Stephan C; Larcher A; McNicholas T; de la Taille A; Freschi M; Lughezzani G; Abrate A; Bini V; Palou Redorta J; Graefen M; Guazzoni G; Lazzeri M Eur Urol; 2015 Jul; 68(1):132-8. PubMed ID: 25139197 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study. Park H; Lee SW; Song G; Kang TW; Jung JH; Chung HC; Kim SJ; Park CH; Park JY; Shin TY; Suh IB; Kim JH J Korean Med Sci; 2018 Mar; 33(11):e94. PubMed ID: 29495138 [TBL] [Abstract][Full Text] [Related]
18. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL. Ng CF; Chiu PK; Lam NY; Lam HC; Lee KW; Hou SS Int Urol Nephrol; 2014 Apr; 46(4):711-7. PubMed ID: 24136184 [TBL] [Abstract][Full Text] [Related]
19. Use of the Prostate Health Index for the Detection of Aggressive Prostate Cancer at Radical Prostatectomy. Mearini L; Nunzi E; Ferri C; Bellezza G; Lolli C; Porrozzi C; Porena M Urol Int; 2015; 95(4):390-9. PubMed ID: 25792149 [TBL] [Abstract][Full Text] [Related]
20. Preoperative prostate health index and %p2PSA as the significant biomarkers of postoperative pathological outcomes of prostate cancer in Korean males: A prospective multi-institutional study. Park H; Lee SW; Song G; Kang TW; Jung JH; Chung HC; Kim SJ; Park JY; Shin TY; Kim JH Investig Clin Urol; 2020 Jan; 61(1):42-50. PubMed ID: 31942462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]